Merck Serono v. TWI Pharmaceuticals: Federal Circuit Affirms Cladribine MS Patent Unpatentable
Merck Serono SA’s appeal to the Federal Circuit failed to save US8377903B2, its patent covering a cladribine dosing regimen for multiple sclerosis. The court affirmed the unpatentability ruling in a case resolved in 253 days, closing off a key exclusivity claim in the MS therapeutics space.
Federal Circuit ends Merck Serono’s cladribine MS patent exclusivity fight
Merck Serono SA, the biopharmaceutical arm of Merck KGaA, brought this appeal before the United States Court of Appeals for the Federal Circuit under Case No. 25-1464, filed February 19, 2025. The dispute centres on US8377903B2, a patent claiming a specific cladribine oral dosing regimen developed for the treatment of relapsing forms of multiple sclerosis. Merck Serono’s cladribine tablet therapy, marketed as Mavenclad, sits at the commercial heart of this dispute. The opposing party, TWI Pharmaceuticals Inc., a Taiwan-based generic pharmaceutical developer, had successfully challenged the patent’s validity at the proceeding below.
The Federal Circuit issued its order on October 30, 2025, affirming the lower tribunal’s finding of unpatentability. The single-word dispositional language — ‘AFFIRMED’ — is unambiguous: the appellate court found no reversible legal or factual error in the underlying invalidity determination. For Merck Serono, affirmance extinguishes the patent’s enforceability and removes a barrier TWI Pharmaceuticals and other generic entrants would have faced. For TWI, the ruling validates its challenge strategy and clears a significant freedom-to-operate concern in the cladribine oral therapy market.
The 253-day resolution is notably swift for a Federal Circuit patent appeal, suggesting the panel may have found the invalidity arguments straightforward or that briefing was streamlined. The public record does not disclose the precise invalidity theory upheld — whether obviousness, anticipation, or another ground — nor does it reveal whether any claims survived. What is clear is that Merck Serono’s appellate arguments were insufficient to disturb the unpatentability finding, and no further appeal within the Federal Circuit system is available absent en banc or Supreme Court petition.
Filing to Unpatentable in 253 days
253 days from filing to Federal Circuit disposition — faster than the median CAFC patent appeal
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means the lower court found no reversible error
When the Federal Circuit issues an ‘AFFIRMED’ disposition, it is confirming that the tribunal below correctly applied the law and that its factual findings were not clearly erroneous. The appellate court does not re-try the case; it reviews for legal error and substantial evidence. Here, the invalidity finding on US8377903B2 was subjected to that standard and survived intact, meaning the patent’s unpatentability is now conclusively established at the federal appellate level.
No reversible error foundMerck Serono loses enforceability of its cladribine dosing patent
Affirmance of unpatentability means US8377903B2 is invalid and unenforceable. Merck Serono cannot assert this patent against TWI Pharmaceuticals or any other party going forward. The ruling forecloses the patent as a competitive barrier for the cladribine oral MS therapy market. Merck Serono’s remaining options are limited to petitioning the Federal Circuit for en banc rehearing or seeking certiorari before the US Supreme Court — both low-probability paths.
Patent invalidated, unenforceableTWI Pharmaceuticals’ invalidity challenge is fully vindicated
TWI Pharmaceuticals successfully defended the invalidity finding through appellate review — the highest federal appellate level below the Supreme Court. The affirmance substantially strengthens TWI’s freedom-to-operate position in developing or commercialising a cladribine oral regimen for multiple sclerosis. Other generic or specialty pharmaceutical developers may similarly benefit, as the ruling extinguishes US8377903B2 as an enforcement risk across the industry.
FTO strengthened, challenge vindicatedCladribine MS market opens to generic competition following affirmance
The Federal Circuit’s affirmance removes a key patent exclusivity pillar for Mavenclad in the US market. Originators relying on dosing-regimen patents as secondary exclusivity layers — a common lifecycle management strategy — should note that such claims face heightened scrutiny. Generic and biosimilar developers active in the MS therapeutics space may find this ruling useful as precedent when challenging similar method-of-treatment or dosing patents in the cladribine or adjacent small-molecule immunomodulator space.
Generic entry risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Merck Serono, SA | Company | Biopharmaceutical company — holder of US8377903B2, cladribine MS dosing regimen patentSearch in Eureka ↗ |
| Defendant | TWI Pharmaceuticals, Inc. | Company | TWI Pharmaceuticals Inc. — generic pharmaceutical developer that successfully challenged the patentSearch in Eureka ↗ |
| Plaintiff counsel | David B. Bassett | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | Emily R. Whelan | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | Helena Rachael MillionPerez | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | Mark Christopher Fleming | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | Nora N. Xu | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff law firm | Wilmer Cutler Pickering Hale & Dorr LLP | Law Firm | Representing Merck Serono, SASearch in Eureka ↗ |
| Defendant counsel | Donald J. Mizerk | Attorney | Counsel for TWI Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Philip D. Segrest | Attorney | Counsel for TWI Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephen Reid Howe | Attorney | Counsel for TWI Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Husch Blackwell LLP | Law Firm | Representing TWI Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s dispositional order — ‘AFFIRMED’ — carries conclusive legal weight. At the appellate level, affirmance signals that the panel found the unpatentability determination below was supported by substantial evidence and free from legal error. The brevity of the order suggests the outcome may have been decided without extensive new legal analysis, consistent with a case where the invalidity grounds were well-established on the record. For Merck Serono, no further relief is available within the Federal Circuit; the patent is invalidated as a matter of final federal appellate authority.
US8377903B2 — Cladribine oral dosing regimen for multiple sclerosis
US8377903B2 was filed under application number US12/766173 and granted to Merck Serono SA. The patent claims a specific oral cladribine dosing regimen for the treatment of multiple sclerosis — a method-of-treatment claim type that protects how a known compound is administered rather than the compound itself. Cladribine is a purine nucleoside analogue with immunosuppressive properties that had prior clinical histories before Merck Serono developed the Mavenclad oral tablet formulation. Method-of-treatment and regimen patents are frequently asserted as secondary lifecycle patents once compound exclusivity weakens.
From a competitive standpoint, US8377903B2 represented a significant enforcement asset for Merck Serono in blocking generic cladribine tablet development targeting the MS indication. Its invalidation by the Federal Circuit removes it as a barrier across the entire US market. For pharmaceutical developers in the MS immunomodulator space — including companies working on oral small-molecule immunosuppressants — the ruling underscores the vulnerability of dosing-schedule claims to prior art challenges, particularly where analogous regimens appear in clinical literature predating the patent application.
Should you run an FTO analysis against US8377903B2 and the Merck Serono cladribine portfolio?
Any pharmaceutical developer, CDMO, or specialty generics company evaluating an oral cladribine programme targeting multiple sclerosis should treat this ruling as a starting point, not a finish line. US8377903B2 has been affirmed unpatentable, but Merck Serono’s broader US and international patent portfolio may include formulation patents, manufacturing process claims, or method-of-use claims covering related aspects of the Mavenclad therapy that remain enforceable. A focused FTO is essential before committing to development or regulatory filing.
PatSnap Eureka’s FTO Search Agent can rapidly map the full Merck Serono cladribine patent family, identify any related continuation or divisional applications, and surface global equivalents that may affect market entry strategies outside the US. Eureka’s claim analysis tools allow R&D and IP teams to assess whether a proposed cladribine dosing protocol design-arounds the now-invalid US8377903B2 scope — or whether other live patents in the family pose residual risk. Run your FTO before your next IND or ANDA filing.
Run a freedom-to-operate analysis on US8377903B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals on MS drug patent invalidity
Explore Federal Circuit cases involving pharmaceutical dosing-regimen patent invalidity challenges in the multiple sclerosis and oral immunomodulator therapy space.
What this case signals for the multiple sclerosis therapeutics IP landscape
The Federal Circuit’s swift affirmance of unpatentability in a cladribine dosing-regimen case has direct implications for MS drug patent strategy and generic challenger playbooks.
Dosing-regimen patents face a high invalidity bar at the Federal Circuit
The affirmance of unpatentability in Merck Serono v. TWI Pharmaceuticals is consistent with a broader trend of Federal Circuit scepticism toward secondary pharmaceutical patents — particularly those claiming dosing schedules or regimens rather than novel compounds. Originators building IP portfolios around approved MS therapies should assess whether their regimen claims clear the obviousness threshold established by prior art in the cladribine and purine analogue literature.
Generic challengers should assess Mavenclad’s remaining patent estate immediately
The loss of US8377903B2 does not necessarily clear the entire patent landscape for cladribine oral therapy. Merck Serono may hold additional US or foreign patents covering formulation, manufacturing, or other aspects of Mavenclad. Any developer pursuing a generic or 505(b)(2) cladribine programme should conduct a thorough FTO analysis against Merck Serono’s full portfolio before assuming open access.
Merck v TWI — key questions answered
The Federal Circuit affirmed the unpatentability of US8377903B2, Merck Serono’s patent covering an oral cladribine dosing regimen for multiple sclerosis treatment. The court found no reversible error in the lower tribunal’s invalidity determination, making the ruling final at the federal appellate level absent Supreme Court review.
US8377903B2 is a US patent granted to Merck Serono SA, filed under application number US12/766173. It covers a specific oral cladribine dosing regimen for treating relapsing forms of multiple sclerosis — the type of secondary, method-of-treatment patent commonly used to extend market exclusivity beyond compound patent expiry. The patent is associated with Merck Serono’s Mavenclad oral tablet product.
Affirmance means US8377903B2 is definitively invalid and cannot be enforced against any party in the United States. Generic or specialty pharmaceutical developers pursuing oral cladribine programmes for MS may find their freedom-to-operate improved with respect to this specific patent. However, they should conduct a full FTO analysis, as Merck Serono may hold additional patents covering related formulation or manufacturing aspects of the cladribine therapy.
The case closed in 253 days from filing to final disposition, which is comparatively swift for a Federal Circuit patent appeal. The public record does not specify the reason for the accelerated timeline. It may suggest the invalidity grounds were well-developed in the record below, that the panel found the legal issues straightforward, or that briefing was efficiently managed by both legal teams.
Following a Federal Circuit affirmance, Merck Serono’s available options are limited. It could petition for en banc rehearing before the full Federal Circuit or seek a writ of certiorari from the US Supreme Court. Both paths carry very low statistical probability of success. For practical IP strategy purposes, US8377903B2 should be treated as finally invalidated.
PatSnap Eureka searches patents and litigation data to answer instantly.